What do systematic reviews say?

NSAIDs vs placebo or active control

The review found no eligible studies for this question.

• Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin vs placebo

• Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 83 participants
  Moderate

Summary of findings ‐ ivacaftor vs placebo

The review found no eligible studies for this question.

• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ ivacaftor vs placebo

The review found no eligible studies for this question.

• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ ivacaftor vs placebo

The review found no eligible studies for this question.

• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biological therapy vs placebo, best supportive care (BSC) or no treatment

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 283 participants
  Low

Prokinetic vs placebo

• Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1774 participants
  Very low

Metronidazole vs placebo

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tetracycline vs placebo

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Doxycycline 40 mg vs placebo

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Azelaic acid vs placebo

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 362 participants
  Moderate

Bethanechol vs placebo

The review found no eligible studies for this question.

• Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FAE vs placebo

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 175 participants
  Low

Topical ivermectin vs placebo

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1371 participants
  High

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Low

Summary of findings ‐ ivacaftor vs placebo

• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 222 participants
  Moderate

Summary of findings ‐ ivacaftor vs placebo

• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 69 participants
  Moderate